Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader

This article was originally published in PharmAsia News

Executive Summary

With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.

You may also be interested in...



Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands

MUMBAI - Explosive growth in India's anti-diabetes medicines market is turning arch rivals into allies. The latest example is of Eli Lilly & Co. combining forces with German giant Boehringer Ingelheim GmbH.

Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases

MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data

Rising Cases Of NCDs Prompts Indian Government To Step Up Healthcare, Screening Programs

MUMBAI - Alarmed by the rapid increase in the number of non-communicable diseases, India's ministry of health and family welfare announced that the recently unveiled National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke will be extended to the entire country over the next five years

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC085271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel